Supplemental Material:  Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD;Lucci,Matthew;Wilson,Kathleen;Kathleen M. Fox, PhD;Wojtynek,Jeffrey;Cooper,Chelsea;Varker,Helen;Chebili,Christina;Igoni Dokubo, MD;

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

December 23, 2020

Brenna L. Brady, PhD, Matthew Lucci, MPH, Kathleen Wilson, MPH, Kathleen M. Fox, PhD, Jeffrey Wojtynek, PharmD, Chelsea Cooper, PharmD, Helen Varker, BS, Christina Larson Chebili, MA, Igoni Dokubo, MD

Evidence-Based Oncology, January 2021, Volume 27, Issue 1

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.